Nandrolone phenpropionate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318304

CAS#: 434-22-0

Description: Nandrolone phenpropionate is a C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.


Price and Availability

Size
Price

100mg
USD 280
Size
Price

Size
Price

Nandrolone phenpropionate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318304
Name: Nandrolone phenpropionate
CAS#: 434-22-0
Chemical Formula: C27H34O3
Exact Mass: 406.2508
Molecular Weight: 406.5571
Elemental Analysis: C, 79.76; H, 8.43; O, 11.81


Synonym: Nandrolone phenpropionate, Durabolin, Fenobolin, NSC-23162E

IUPAC/Chemical Name: [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate

SMILES Code: O=C(O[C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4([H])[C@@]3([H])CC[C@]12C)=O)CCC5=CC=CC=C5


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Kahn SB, Conroy JF, Brodsky I. Effect of nandrolone phenpropionate on myelopoiesis. J Med. 1974;5(6):303-9. PubMed PMID: 4528544.

2: Levin SM, Simkin A, Naor E, Robin GC, Goldenberg A, Dorfman H. A comparison of assay technics in experimental disuse osteoporosis. The effect of nandrolone phenpropionate (Durabolin). Clin Orthop Relat Res. 1972 Jan-Feb;82:246-52. PubMed PMID: 5011032.

3: HAMILTON LD, BENNETT JL, SILVER J. NANDROLONE PHENPROPIONATE IN THE TREATMENT OF GERIATRIC PATIENTS WITH CHRONIC BRAIN DAMAGE. J Am Geriatr Soc. 1964 Apr;12:373-8. PubMed PMID: 14136815.

4: KASICH AM. CLINICAL EVALUATION OF NANDROLONE PHENPROPIONATE IN PATIENTS WITH GASTROINTESTINAL DISEASE. Am J Gastroenterol. 1963 Dec;40:628-33. PubMed PMID: 14099447.

5: MARTINS JK. Use of nandrolone phenpropionate in refractory anemias. Curr Ther Res Clin Exp. 1961 Dec;3:512-9. PubMed PMID: 14470556.

6: BROWN IA, JAMES EM. Nandrolone-phenpropionate in progressive muscular dystrophy. Arch Pediatr. 1961 Nov;78:421-31. PubMed PMID: 13873658.

7: BANGHART HE. Osteoporosis treatment with nandrolone phenpropionate. Pa Med J. 1961 Aug;64:984-6. PubMed PMID: 13686583.

8: SZUJEWSKI HA. Nandrolone phenpropionate: a new palliative agent in the management of mammary carcinoma. Am Pract Dig Treat. 1959 Dec;10:2157-9. PubMed PMID: 13836459.